目的运用生物信息学分析铜死亡CDKN2A基因在肺腺癌中的表达水平、预后价值、免疫细胞浸润、相关基因筛选、功能富集分析及潜在中药预测,以期为临床治疗提供参考。方法使用GEPIA2和UALCAN,研究CDKN2A在肺腺癌患者中的表达情况,研究它与...目的运用生物信息学分析铜死亡CDKN2A基因在肺腺癌中的表达水平、预后价值、免疫细胞浸润、相关基因筛选、功能富集分析及潜在中药预测,以期为临床治疗提供参考。方法使用GEPIA2和UALCAN,研究CDKN2A在肺腺癌患者中的表达情况,研究它与患者的年龄、性别和种族等之间存在的相关性;使用KM-plotter来评估预后价值;使用TIMER 2.0进行免疫浸润相关性分析;利用LinkedOmics数据库筛选相关基因,进行功能富集分析;利用COREMINE数据库进行中药预测,TCMSP数据库、HERB数据库及Swiss ADME平台筛选出上述中药有效活性成分,Cytoscape软件绘制“中药-活性成分”网络图。结果按照P<0.05检验水平,CDKN2A在肺腺癌组织中显著高表达,与患者吸烟、种族、TP53突变有关,与年龄、性别、肿瘤分级、肿瘤分期无关。CDKN2A高表达患者预后差(HR=1.73;P=0.00024)。CDKN2A与多种免疫细胞浸润相关。基因本体(gene ontology,GO)富集分析显示正相关基因主要参与细胞周期、ncRNA 3′-末端处理、核酸磷酸二酯键水解过程,表达于含细胞蛋白复合物、染色体组织,基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路分析显示正相关基因参与细胞周期与DNA复制过程。预测出虎刺、蜂房、兰花根(春兰根)等9味中药,其四气以温、平为主,五味以甘、辛、苦为主,归经主要归肝、肺、脾经,有效活性成分有73种。结论CDKN2A在肺腺癌组织中显著高表达,高表达患者预后差。虎刺、蜂房、兰花根等9味中药可能是治疗CDKN2A基因突变的肺腺癌患者的潜在药物。展开更多
Background:The cyclin-dependent kinase inhibitor 2a(CDKN2A)gene,identified as the multiple tumor suppressor gene,functions as a regulatory gene implicated in cancer pathogenesis.Its significance lies in its pivotal in...Background:The cyclin-dependent kinase inhibitor 2a(CDKN2A)gene,identified as the multiple tumor suppressor gene,functions as a regulatory gene implicated in cancer pathogenesis.Its significance lies in its pivotal involvement in the genesis of various tumors;notwithstanding,the precise connection between CDKN2A and c olon adenocarcinoma(COAD)remains undisclosed.Methods:The objective of this research was to assess the predictive importance of CDKN2A in COAD by analyzing data from The Cancer Genome Atlas database.Logistic regression,signed rank test,Wilcoxon test,and Kruskal-Wallis test were used to examine CDKN2A expression levels and clinicopathological features.Univariate and multivariate Cox r egression analyses and Kaplan-Meier analysis found prognostic variables.Additionally,gene set enrichment analysis identified key CDKN2A expression pathways.The study additionally examined CDKN2A expression with tumor immune infiltration using The Cancer Genome Atlas data and single sample gene set enrichment analysis.Results:The results of this investigation indicated a substantial connection between higher CDKN2A expression and negative outcomes in terms of overall survival and disease-related survival among COAD patients.Gene set enrichment analysis indicated a tight link between CDKN2A and both the cell cycle and hedgehog signaling pathways.Subsequent evaluation employing single sample gene set enrichment analysis demonstrated a positive link between CDKN2A expression with infiltration by iDCs,whereas a negative correlation was detected with infiltration by helper T cells.Conclusion:In conclusion,the present study gives strong data supporting the predictive value of CDKN2A and its possible usefulness as a biomarker for COAD.Additionally,our results show a reasonable link between CDKN2A expression and immune influx in COAD,putting light on the role of CDKN2A in the control of the tumor microenvironment.Nevertheless,additional studies are needed to confirm the underlying mechanisms of these relationships and to discover the therapeutic possibilities of targeting CDKN2A in the treatment of COAD.展开更多
目的:评估细胞周期依赖性激酶抑制基因(CDKN2A)突变与晚期非小细胞肺癌(NSCLC)患者的临床病理特征和预后的关系。方法:采用第二代测序技术筛选肿瘤标本中的CDKN2A基因突变。卡方检验分析CDKN2A基因突变与晚期NSCLC临床病理特征之间的相...目的:评估细胞周期依赖性激酶抑制基因(CDKN2A)突变与晚期非小细胞肺癌(NSCLC)患者的临床病理特征和预后的关系。方法:采用第二代测序技术筛选肿瘤标本中的CDKN2A基因突变。卡方检验分析CDKN2A基因突变与晚期NSCLC临床病理特征之间的相关性。Logistic回归分析CDKN2A基因突变与临床一线治疗评效之间的相关性。Kaplan-Meier曲线和COX模型评估患者生存。结果:NSCLC患者CDKN2A基因突变率为3.81%(8/210)。CDKN2A基因突变在鳞状细胞癌患者中更常见(P=0.005)。多数CDKN2A基因突变型患者一线治疗评效是疾病进展(PD),而野生型患者多为疾病控制(DCR)(P=0.012)。CDKN2A基因突变型患者的中位生存时间(OS)明显短于野生型患者(19.1 vs 42.8个月,P=0.010),并且突变型患者的无进展生存时间(PFS)也明显缩短(3.5 vs 9.7个月,P=0.001)。多因素分析显示CDKN2A基因突变、T_4期、淋巴结转移和ECOG高评分是影响晚期NSCLC患者生存的独立危险因素。结论:CDKN2A基因突变对晚期NSCLC患者的临床病理特征和预后有重要影响。CDKN2A基因突变患者的生存期明显缩短。展开更多
文摘目的运用生物信息学分析铜死亡CDKN2A基因在肺腺癌中的表达水平、预后价值、免疫细胞浸润、相关基因筛选、功能富集分析及潜在中药预测,以期为临床治疗提供参考。方法使用GEPIA2和UALCAN,研究CDKN2A在肺腺癌患者中的表达情况,研究它与患者的年龄、性别和种族等之间存在的相关性;使用KM-plotter来评估预后价值;使用TIMER 2.0进行免疫浸润相关性分析;利用LinkedOmics数据库筛选相关基因,进行功能富集分析;利用COREMINE数据库进行中药预测,TCMSP数据库、HERB数据库及Swiss ADME平台筛选出上述中药有效活性成分,Cytoscape软件绘制“中药-活性成分”网络图。结果按照P<0.05检验水平,CDKN2A在肺腺癌组织中显著高表达,与患者吸烟、种族、TP53突变有关,与年龄、性别、肿瘤分级、肿瘤分期无关。CDKN2A高表达患者预后差(HR=1.73;P=0.00024)。CDKN2A与多种免疫细胞浸润相关。基因本体(gene ontology,GO)富集分析显示正相关基因主要参与细胞周期、ncRNA 3′-末端处理、核酸磷酸二酯键水解过程,表达于含细胞蛋白复合物、染色体组织,基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路分析显示正相关基因参与细胞周期与DNA复制过程。预测出虎刺、蜂房、兰花根(春兰根)等9味中药,其四气以温、平为主,五味以甘、辛、苦为主,归经主要归肝、肺、脾经,有效活性成分有73种。结论CDKN2A在肺腺癌组织中显著高表达,高表达患者预后差。虎刺、蜂房、兰花根等9味中药可能是治疗CDKN2A基因突变的肺腺癌患者的潜在药物。
基金Guizhou Provincial Department of Science and Technology Natural Science Foundation(No Foundation-ZK[2022])the Guizhou Provincial Health Commission Science and Technology Fund(No.GZWKJ2023-135)the Science Foundation of 925th Hospital(No.2023[3],No.2022[3/4]).
文摘Background:The cyclin-dependent kinase inhibitor 2a(CDKN2A)gene,identified as the multiple tumor suppressor gene,functions as a regulatory gene implicated in cancer pathogenesis.Its significance lies in its pivotal involvement in the genesis of various tumors;notwithstanding,the precise connection between CDKN2A and c olon adenocarcinoma(COAD)remains undisclosed.Methods:The objective of this research was to assess the predictive importance of CDKN2A in COAD by analyzing data from The Cancer Genome Atlas database.Logistic regression,signed rank test,Wilcoxon test,and Kruskal-Wallis test were used to examine CDKN2A expression levels and clinicopathological features.Univariate and multivariate Cox r egression analyses and Kaplan-Meier analysis found prognostic variables.Additionally,gene set enrichment analysis identified key CDKN2A expression pathways.The study additionally examined CDKN2A expression with tumor immune infiltration using The Cancer Genome Atlas data and single sample gene set enrichment analysis.Results:The results of this investigation indicated a substantial connection between higher CDKN2A expression and negative outcomes in terms of overall survival and disease-related survival among COAD patients.Gene set enrichment analysis indicated a tight link between CDKN2A and both the cell cycle and hedgehog signaling pathways.Subsequent evaluation employing single sample gene set enrichment analysis demonstrated a positive link between CDKN2A expression with infiltration by iDCs,whereas a negative correlation was detected with infiltration by helper T cells.Conclusion:In conclusion,the present study gives strong data supporting the predictive value of CDKN2A and its possible usefulness as a biomarker for COAD.Additionally,our results show a reasonable link between CDKN2A expression and immune influx in COAD,putting light on the role of CDKN2A in the control of the tumor microenvironment.Nevertheless,additional studies are needed to confirm the underlying mechanisms of these relationships and to discover the therapeutic possibilities of targeting CDKN2A in the treatment of COAD.
文摘目的:评估细胞周期依赖性激酶抑制基因(CDKN2A)突变与晚期非小细胞肺癌(NSCLC)患者的临床病理特征和预后的关系。方法:采用第二代测序技术筛选肿瘤标本中的CDKN2A基因突变。卡方检验分析CDKN2A基因突变与晚期NSCLC临床病理特征之间的相关性。Logistic回归分析CDKN2A基因突变与临床一线治疗评效之间的相关性。Kaplan-Meier曲线和COX模型评估患者生存。结果:NSCLC患者CDKN2A基因突变率为3.81%(8/210)。CDKN2A基因突变在鳞状细胞癌患者中更常见(P=0.005)。多数CDKN2A基因突变型患者一线治疗评效是疾病进展(PD),而野生型患者多为疾病控制(DCR)(P=0.012)。CDKN2A基因突变型患者的中位生存时间(OS)明显短于野生型患者(19.1 vs 42.8个月,P=0.010),并且突变型患者的无进展生存时间(PFS)也明显缩短(3.5 vs 9.7个月,P=0.001)。多因素分析显示CDKN2A基因突变、T_4期、淋巴结转移和ECOG高评分是影响晚期NSCLC患者生存的独立危险因素。结论:CDKN2A基因突变对晚期NSCLC患者的临床病理特征和预后有重要影响。CDKN2A基因突变患者的生存期明显缩短。
